Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.39 |
| ▸ | IDH1 | O75874 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 6/20 | 0.34 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.32 |
| ▸ | MELK | Q14680 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6195680 | 1.00 | ASIC3 (0.42) | ASIC3FFAR1FFAR4PYCR1IDH1 | |
| SCHEMBL6192542 | 0.93 | ASIC3 (0.47) | ASIC3FFAR1FFAR4IDH1MMP13 | |
| SCHEMBL6196285 | 0.86 | ASIC3 (0.42) | ASIC3FFAR1FFAR4IDH1MMP13 | |
| SCHEMBL6195037 | 0.86 | ASIC3 (0.42) | ASIC3FFAR1FFAR4IDH1MMP13 | |
| SCHEMBL6193080 | 0.86 | ASIC3 (0.42) | ASIC3FFAR1FFAR4IDH1MMP13 | |
| SCHEMBL6195577 | 0.86 | ASIC3 (0.42) | ASIC3FFAR1FFAR4IDH1MMP13 | |
| SCHEMBL6194646 | 0.86 | ASIC3 (0.42) | ASIC3FFAR1FFAR4IDH1MMP13 | |
| SCHEMBL6193088 | 0.86 | MMP13 (0.46) | ASIC3FFAR1FFAR4IDH1MMP13 | |
| SCHEMBL6194527 | 0.86 | MMP13 (0.46) | ASIC3FFAR1FFAR4IDH1MMP13 | |
| SCHEMBL6195650 | 0.86 | ASIC3 (0.42) | ASIC3FFAR1FFAR4IDH1MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539163-A1 | 4-HYDROXYQUINOLINE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040043983-A1 | Naphthalene derivatives as matrix metalloproteinase inhibitors | LI JIE JACK (US) | 2004-03-04 | — | — | US | disclosed |
| WO-2004014377-A1 | 4-HYDROXYQUINOLINE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043983-A1 | Naphthalene derivatives as matrix metalloproteinase inhibitors | MMP9, MMP8, MMP13 | ASIC3 1686/4885FFAR1 2162/4885FFAR4 2725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.